Vertex Pharmaceuticals
Registered Principal Details
Business Or Interest:
Vertex is a global biotechnology company that aims to discover, develop and commercialize innovative new medicines so people with serious diseases can lead better lives.
Lobbying Interests:
Engage on legislation that impacts access to innovative medicines and therapies; assist with disease awareness initiatives.
CEO Name:
Reshma Kewalramani
Vertex is a global biotechnology company that aims to discover, develop and commercialize innovative new medicines so people with serious diseases can lead better lives.
Lobbying Interests:
Engage on legislation that impacts access to innovative medicines and therapies; assist with disease awareness initiatives.
CEO Name:
Reshma Kewalramani
Contact
LB
Libby Brunsvold
50 Northern Avenue
Boston, MA 20001
(617) 961-7770
Libby_Brunsvold@vrtx.com
http://www.vrtx.com
50 Northern Avenue
Boston, MA 20001
(617) 961-7770
Libby_Brunsvold@vrtx.com
http://www.vrtx.com
Authorized Lobbyists
| Lobbyist Name | Exclusive Duties | Authorized On | Withdrawn On |
|---|---|---|---|
| Elizabeth Brunsvold | Exclusive Duties No | Authorized On 12/23/2022 | Withdrawn On N/A |
| Tony Langenohl | Exclusive Duties No | Authorized On 12/23/2022 | Withdrawn On N/A |
Lobbying Interests
Legislative Bills/Resolutions
Assembly Bill 103
Toggle details
Assembly Bill 103
Relating to: application of prescription drug payments to health insurance cost-sharing requirements.
Bill Text and History
3/18/2023
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Relating to: application of prescription drug payments to health insurance cost-sharing requirements.
Bill Text and History
For
Notification Date3/18/2023
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Assembly Bill 773
Toggle details
Assembly Bill 773
Relating to: regulation of pharmacy benefit managers, fiduciary and disclosure requirements on pharmacy benefit managers, and application of prescription drug payments to health insurance cost-sharing requirements. (FE)
Bill Text and History
12/9/2023
First Communication Date
12/9/2023
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has communicated on this matter.
Relating to: regulation of pharmacy benefit managers, fiduciary and disclosure requirements on pharmacy benefit managers, and application of prescription drug payments to health insurance cost-sharing requirements. (FE)
Bill Text and History
For
Notification Date12/9/2023
First Communication Date
12/9/2023
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has communicated on this matter.
Assembly Joint Resolution 111
Toggle details
Assembly Joint Resolution 111
Relating to: observing February 29, 2024, as Rare Disease Day in Wisconsin.
Bill Text and History
2/3/2024
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Relating to: observing February 29, 2024, as Rare Disease Day in Wisconsin.
Bill Text and History
For
Notification Date2/3/2024
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Senate Bill 100
Toggle details
Senate Bill 100
Relating to: application of prescription drug payments to health insurance cost-sharing requirements.
Bill Text and History
3/7/2023
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Relating to: application of prescription drug payments to health insurance cost-sharing requirements.
Bill Text and History
For
Notification Date3/7/2023
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Senate Bill 737
Toggle details
Senate Bill 737
Relating to: regulation of pharmacy benefit managers, fiduciary and disclosure requirements on pharmacy benefit managers, and application of prescription drug payments to health insurance cost-sharing requirements. (FE)
Bill Text and History
12/4/2023
First Communication Date
12/4/2023
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has communicated on this matter.
Relating to: regulation of pharmacy benefit managers, fiduciary and disclosure requirements on pharmacy benefit managers, and application of prescription drug payments to health insurance cost-sharing requirements. (FE)
Bill Text and History
For
Notification Date12/4/2023
First Communication Date
12/4/2023
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has communicated on this matter.
Senate Joint Resolution 102
Toggle details
Senate Joint Resolution 102
Relating to: observing February 29, 2024, as Rare Disease Day in Wisconsin.
Bill Text and History
2/3/2024
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Relating to: observing February 29, 2024, as Rare Disease Day in Wisconsin.
Bill Text and History
For
Notification Date2/3/2024
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Topics Not Yet Assigned A Bill Or Rule Number
Development, drafting or introduction of a proposal relating to
Development, drafting or introduction of a proposal related to sickle disease awareness month.
Development, drafting or introduction of a proposal related to sickle disease awareness month.
Action Intended To Affect
Both Legislative matter and rule
Notification Date
12/22/2022
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Both Legislative matter and rule
Notification Date
12/22/2022
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Development, drafting or introduction of a proposal relating to
Development, drafting or introduction of a proposal related to the treatment of sickle cell disease
Development, drafting or introduction of a proposal related to the treatment of sickle cell disease
Action Intended To Affect
Both Legislative matter and rule
Notification Date
12/22/2022
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Both Legislative matter and rule
Notification Date
12/22/2022
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Development, drafting or introduction of a proposal relating to
Development, drafting or introduction of a proposal Medicaid drug coverage process and procedure.
Development, drafting or introduction of a proposal Medicaid drug coverage process and procedure.
Action Intended To Affect
Both Legislative matter and rule
Notification Date
12/22/2022
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Both Legislative matter and rule
Notification Date
12/22/2022
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Development, drafting or introduction of a proposal related to the creation of a rare disease advisory council.
Development, drafting or introduction of a proposal relating to
Development, drafting or introduction of a proposal related to the creation of a rare disease advisory council.
Development, drafting or introduction of a proposal related to the creation of a rare disease advisory council.
Action Intended To Affect
Both Legislative matter and rule
Notification Date
12/22/2022
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Both Legislative matter and rule
Notification Date
12/22/2022
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Development, drafting or introduction of a proposal relating to regulation of pharmaceutical manufacturers.
Development, drafting or introduction of a proposal relating to
Development, drafting or introduction of a proposal relating to regulation of pharmaceutical manufacturers.
Development, drafting or introduction of a proposal relating to regulation of pharmaceutical manufacturers.
Action Intended To Affect
Both Legislative matter and rule
Notification Date
12/22/2022
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Both Legislative matter and rule
Notification Date
12/22/2022
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Development, drafting or introduction of a proposal relating to
Development, drafting or introduction of a proposal relating to treatment of cyclic fibrosis.
Development, drafting or introduction of a proposal relating to treatment of cyclic fibrosis.
Action Intended To Affect
Both Legislative matter and rule
Notification Date
12/22/2022
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Both Legislative matter and rule
Notification Date
12/22/2022
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Total Lobbying Effort
| 2023 January - June |
2023 July - December |
2024 January - June |
2024 July - December |
Total | |
|---|---|---|---|---|---|
| Total Lobbying Expenditures | 2023 January - June $24,000.00 |
2023 July - December $24,000.00 |
2024 January - June $0.00 |
2024 July - December $24,000.00 |
Total $72,000.00 |
| Total Hours Communicating | 2023 January - June 1.50 |
2023 July - December 0.00 |
2024 January - June 1.00 |
2024 July - December 0.00 |
Total 2.50 |
| Total Hours Other | 2023 January - June 22.00 |
2023 July - December 19.00 |
2024 January - June 5.50 |
2024 July - December 11.50 |
Total 58.00 |
Percent Allocation of Lobbying Effort
Legislative Bills/Resolutions
Relating to: application of prescription drug payments to health insurance cost-sharing requirements.
| 2023 January - June |
2023 July - December |
2024 January - June |
2024 July - December |
Total |
|---|---|---|---|---|
| 2023 January - June 25% |
2023 July - December 35% |
2024 January - June |
2024 July - December |
Total 21% |
Relating to: application of prescription drug payments to health insurance cost-sharing requirements.
| 2023 January - June |
2023 July - December |
2024 January - June |
2024 July - December |
Total |
|---|---|---|---|---|
| 2023 January - June 25% |
2023 July - December 35% |
2024 January - June |
2024 July - December |
Total 21% |
Relating to: regulation of pharmacy benefit managers, fiduciary and disclosure requirements on pharmacy benefit managers, and application of prescription drug payments to health insurance cost-sharing requirements. (FE)
| 2023 January - June |
2023 July - December |
2024 January - June |
2024 July - December |
Total |
|---|---|---|---|---|
| 2023 January - June |
2023 July - December 20% |
2024 January - June 40% |
2024 July - December |
Total 12% |
Relating to: observing February 29, 2024, as Rare Disease Day in Wisconsin.
| 2023 January - June |
2023 July - December |
2024 January - June |
2024 July - December |
Total |
|---|---|---|---|---|
| 2023 January - June |
2023 July - December |
2024 January - June 10% |
2024 July - December |
Total 2% |
Relating to: regulation of pharmacy benefit managers, fiduciary and disclosure requirements on pharmacy benefit managers, and application of prescription drug payments to health insurance cost-sharing requirements. (FE)
| 2023 January - June |
2023 July - December |
2024 January - June |
2024 July - December |
Total |
|---|---|---|---|---|
| 2023 January - June |
2023 July - December |
2024 January - June 40% |
2024 July - December |
Total 5% |
Budget Bill Subjects
No budget bill subjects found.
Administrative Rulemaking Proceedings
No administrative rulemaking proceedings found.
Topics Not Yet Assigned A Bill Or Rule Number
| 2023 January - June |
2023 July - December |
2024 January - June |
2024 July - December |
Total |
|---|---|---|---|---|
| 2023 January - June 10% |
2023 July - December |
2024 January - June |
2024 July - December |
Total 4% |
Development, drafting or introduction of a proposal relating to regulation of pharmaceutical manufacturers.
| 2023 January - June |
2023 July - December |
2024 January - June |
2024 July - December |
Total |
|---|---|---|---|---|
| 2023 January - June 20% |
2023 July - December |
2024 January - June |
2024 July - December 50% |
Total 17% |
| 2023 January - June |
2023 July - December |
2024 January - June |
2024 July - December |
Total |
|---|---|---|---|---|
| 2023 January - June 20% |
2023 July - December |
2024 January - June |
2024 July - December |
Total 8% |
| 2023 January - June |
2023 July - December |
2024 January - June |
2024 July - December |
Total |
|---|---|---|---|---|
| 2023 January - June |
2023 July - December 10% |
2024 January - June 10% |
2024 July - December 50% |
Total 14% |
Minor Efforts
No minor efforts found.
Other Matters
No other matters found.